Kleindorfer Dawn, Xu Yingying, Moomaw Charles J, Khatri Pooja, Adeoye Opeolu, Hornung Richard
Department of Neurology, University of Cincinnati, Ohio 45267-0525, USA.
Stroke. 2009 Nov;40(11):3580-4. doi: 10.1161/STROKEAHA.109.554626. Epub 2009 Oct 1.
Previously, we have estimated US national rates of recombinant tissue plasminogen activator (rt-PA) use to be 1.8% to 3.0% of all ischemic stroke patients. However, we hypothesized that the rate of rt-PA use may vary widely depending on regional variation, and that a large percentage of the US population likely does not have access to hospitals using rt-PA regularly. We describe the US geographic distribution of hospitals using rt-PA for acute ischemic stroke.
This analysis used the MEDPAR database, which is a claims-based dataset that contains every fee-for-service Medicare-eligible hospital discharge in the US. Cases potentially eligible for rt-PA treatment based on diagnosis were defined as those with a hospital DRG code of 14, 15, or 559, and that also had an ICD-9 code of 433, 434, or 436. Thrombolysis use was defined as an ICD-9 code of 99.1. Study interval was July 1, 2005 to June 30, 2007. Hospital locations were mapped using ArcView software; population densities and regions of the US are based on US Census 2000.
There were 4750 hospitals in the MEDPAR database, which included 495 186 ischemic stroke admissions during the study period. Of these hospitals, 64% had no reported treatments with rt-PA for ischemic stroke, and 0.9% reported >10% treatment rates within the MEDPAR dataset. Bed size, rural or underserved designation, and population density were significantly associated with reported rt-PA treatment rates, and remained significant in the multivariable regression. Approximately 162 million US citizens reside in counties containing a hospital reporting a >or=2.4% treatment rate within the MEDPAR dataset.
We report the first description of US hospital rt-PA treatment rates by hospital. Unfortunately, we found that 64% of US hospitals did not report giving rt-PA at all within the MEDPAR database within a 2-year period. These tended to be hospitals that were smaller (average bed size of 95), located in less densely populated areas, or located in the South or Midwest. In addition, 40% of the US population resides in counties without a hospital that administered rt-PA to at least 2.4% of ischemic stroke patients, although distinguishing transferred patients is problematic within administrative datasets. Such national-based resource-utilization data is important for planning at the local and national level, especially for such initiatives as telemedicine, to reach underserved areas.
此前,我们估计美国重组组织型纤溶酶原激活剂(rt-PA)的全国使用比例为所有缺血性脑卒中患者的1.8%至3.0%。然而,我们推测rt-PA的使用比例可能因地区差异而有很大不同,并且美国很大一部分人口可能无法定期前往使用rt-PA的医院。我们描述了美国使用rt-PA治疗急性缺血性脑卒中的医院的地理分布情况。
本分析使用了医疗费用报销数据库(MEDPAR),该数据库是一个基于索赔的数据集,包含美国所有符合医疗保险报销条件的按服务收费的医院出院记录。根据诊断可能符合rt-PA治疗条件的病例定义为医院诊断相关组(DRG)代码为14、15或559,且国际疾病分类第九版(ICD-9)代码为433、434或436的病例。溶栓治疗的使用定义为ICD-9代码为99.1。研究区间为2005年7月1日至2007年6月30日。使用ArcView软件绘制医院位置图;美国的人口密度和地区基于2000年美国人口普查数据。
MEDPAR数据库中有4750家医院,在研究期间包括495186例缺血性脑卒中住院病例。在这些医院中,64%未报告对缺血性脑卒中使用rt-PA进行治疗,0.9%在MEDPAR数据集中报告的治疗率>10%。床位规模、农村或服务不足地区的指定以及人口密度与报告的rt-PA治疗率显著相关,在多变量回归中仍然显著。约1.62亿美国公民居住在MEDPAR数据集中有医院报告治疗率≥2.4%的县。
我们首次按医院报告了美国医院rt-PA的治疗率。遗憾的是,我们发现美国64%的医院在MEDPAR数据库的两年期间内根本未报告使用rt-PA。这些医院往往规模较小(平均床位95张),位于人口密度较低的地区,或位于南部或中西部。此外,40%的美国人口居住在没有医院对至少2.4%的缺血性脑卒中患者使用rt-PA的县,尽管在行政数据集中区分转诊患者存在问题。这种基于全国的资源利用数据对于地方和国家层面的规划很重要,特别是对于远程医疗等旨在覆盖服务不足地区的举措。